Clinical Trial Update: Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder. [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Biolab Zolpidem Orodispersible in multiple doses for maintenance insomnia disorder across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia Disorder

Drugs mentioned

• Zolpidem Orodispersible (zolpidem)

Snippet

Sponsor: Biolab Sanus Farmaceutica | Conditions: Insomnia Disorder | Phase 2, Phase 3 | Status: UNKNOWN